Charles Schwab
CCCC icon

Charles Schwab’s C4 Therapeutics CCCC Stock Holding History

Charles Schwab’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.65M Buy
781,060
+328,832
+73% +$1.12M ﹤0.01% 2593
2026
Q1 		$1.19M Buy
452,228
+2,796
+0.6% +$6.58K ﹤0.01% 2855
2025
Q4 		$858K Buy
449,432
+98,826
+28% +$234K ﹤0.01% 2983
2025
Q3 		$778K Buy
350,606
+18,709
+6% +$44.9K ﹤0.01% 3032
2025
Q2 		$475K Sell
331,897
-142,946
-30% -$208K ﹤0.01% 3155
2025
Q1 		$760K Sell
474,843
-11,523
-2% -$34.4K ﹤0.01% 2938
2024
Q4 		$1.75M Buy
486,366
+3,437
+0.7% +$17.1K ﹤0.01% 2717
2024
Q3 		$2.75M Sell
482,929
-6,029
-1% -$36.3K ﹤0.01% 2606
2024
Q2 		$2.26M Buy
488,958
+221,529
+83% +$1.32M ﹤0.01% 2669
2024
Q1 		$2.18M Buy
267,429
+14,719
+6% +$114K ﹤0.01% 2563
2023
Q4 		$1.43M Buy
252,710
+4,458
+2% +$10.2K ﹤0.01% 2713
2023
Q3 		$462K Buy
248,252
+17,218
+7% +$52.5K ﹤0.01% 3067
2023
Q2 		$635K Sell
231,034
-85,975
-27% -$276K ﹤0.01% 2941
2023
Q1 		$995K Sell
317,009
-39,643
-11% -$233K ﹤0.01% 2734
2022
Q4 		$2.1M Buy
356,652
+4,527
+1% +$37.5K ﹤0.01% 2561
2022
Q3 		$3.09M Buy
352,125
+78,936
+29% +$819K ﹤0.01% 2453
2022
Q2 		$2.06M Buy
273,189
+52
+0% +$458 ﹤0.01% 2562
2022
Q1 		$6.63M Buy
273,137
+8,486
+3% +$206K ﹤0.01% 2151
2021
Q4 		$8.52M Buy
264,651
+4,199
+2% +$166K ﹤0.01% 2082
2021
Q3 		$11.6M Buy
260,452
+119,858
+85% +$5.13M ﹤0.01% 1916
2021
Q2 		$5.32M Buy
140,594
+70,882
+102% +$2.54M ﹤0.01% 2319
2021
Q1 		$2.58M Buy
69,712
+2,970
+4% +$118K ﹤0.01% 2591
2020
Q4 		$2.21M Buy
+66,742
New +$1.94M ﹤0.01% 2567

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Charles Schwab's CCCC Position: Q2 2026 in Review

Charles Schwab increased its C4 Therapeutics (CCCC) stake by 73% in Q2 2026, buying an estimated $1.12M and bringing the position to 781,060 shares worth $3.65M. The position accounts for ﹤0.01% of the portfolio, ranked #2593.

Charles Schwab first reported a position in CCCC in Q4 2020 and has held it in 23 quarters since. The position peaked at $11.6M in Q3 2021. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Charles Schwab held 781,060 shares of C4 Therapeutics worth $3.65M as of Q2 2026.
  • Charles Schwab bought 328,832 C4 Therapeutics shares in Q2 2026, an estimated $1.12M.
  • C4 Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2593 holding.
  • Charles Schwab first reported a position in C4 Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Charles Schwab's C4 Therapeutics position peaked at $11.6M in Q3 2021.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.